UBS lowered the firm’s price target on Acuren (TIC) to $11.50 from $12 and keeps a Neutral rating on the shares. Acuren announced an agreement to acquire NV5 (NVEE), which has good strategic appeal, though Q1 EBITDA was softer amid stronger revenue, the analyst tells investors in a research note.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TIC: